Myriad to Double Sales Force for Prolaris Prostate Cancer Dx
February 01, 2012
Myriad to Double Sales Force for Prolaris Prostate Cancer Dx
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Continuing Revenue Growth in Third Quarter, Myriad Keeps Focus on Diversifying MDx Product Portfolio
May 8, 2013 / Pharmacogenomics Reporter - Posting 11 Percent Revenue Growth in FY2011, Myriad Focuses on Growing MDx Pipeline
August 10, 2011 / Pharmacogenomics Reporter - Myriad Expects BRACAnalysis to Remain Best Seller in 'Post-Patent' Era
February 6, 2013 / Pharmacogenomics Reporter - Reporting 27 Percent Q3 Jump, Myriad Outlines Three-Pronged Plan for Diversifying Revenue Base
May 2, 2012 / Pharmacogenomics Reporter - Prostate Cancer MDx Competition Heating Up; New Data from Genomic Health, Myriad
May 15, 2013 / Pharmacogenomics Reporter